Technical Analysis for NKTX - Nkarta, Inc.

Grade Last Price % Change Price Change
grade D 29.12 -3.54% -1.07
NKTX closed down 3.54 percent on Tuesday, October 20, 2020, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical NKTX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Multiple of Ten Bearish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -3.54%
Multiple of Ten Bullish Other -3.54%
Crossed Above 20 DMA Bullish -9.00%
Pocket Pivot Bullish Swing Setup -9.00%
50 DMA Support Bullish -6.58%
Older End-of-Day Gignals for NKTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 12 hours ago
20 DMA Resistance about 12 hours ago
10 DMA Resistance about 12 hours ago
Up 5% about 12 hours ago
Up 3% about 12 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Cancer Immunotherapy Immune System Cancer Treatments Gene Therapy Virotherapy Tumor Lymphoma Therapies For Cancer Chimeric Antigen Receptor T Cell Antigen

Is NKTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 58.69
52 Week Low 22.4602
Average Volume 204,597
200-Day Moving Average 0.00
50-Day Moving Average 29.38
20-Day Moving Average 31.13
10-Day Moving Average 31.10
Average True Range 3.09
ADX 11.61
+DI 19.85
-DI 22.38
Chandelier Exit (Long, 3 ATRs ) 26.46
Chandelier Exit (Short, 3 ATRs ) 36.53
Upper Bollinger Band 34.13
Lower Bollinger Band 28.13
Percent B (%b) 0.16
BandWidth 19.25
MACD Line -0.01
MACD Signal Line 0.31
MACD Histogram -0.3154
Fundamentals Value
Market Cap 951.48 Million
Num Shares 32.7 Million
EPS -0.88
Price-to-Earnings (P/E) Ratio -33.19
Price-to-Sales 59265.51
Price-to-Book 33.88
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.48
Resistance 3 (R3) 35.72 33.85 34.42
Resistance 2 (R2) 33.85 32.23 33.73 34.07
Resistance 1 (R1) 31.48 31.23 30.55 31.24 33.71
Pivot Point 29.61 29.61 29.14 29.49 29.61
Support 1 (S1) 27.24 27.99 26.31 27.00 24.53
Support 2 (S2) 25.37 26.99 25.25 24.17
Support 3 (S3) 23.00 25.37 23.82
Support 4 (S4) 22.76